Lv1
20 积分 2021-12-06 加入
Combination locoregional and systemic therapies in hepatocellular carcinoma
2小时前
待确认
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
2小时前
已完结
Navigating resistance to ALK inhibitors in the lorlatinib era: a comprehensive perspective on NSCLC
1天前
已完结
Shorter Time to Achieve a Major Molecular Response (MMR) Is Predictive of a Faster Complete Molecular Response in CML: A Study of Characteristics and Outcomes of a Cohort of CML Patients in MMR
1个月前
已关闭
The Evolution of Treatment-Free Remission
1个月前
已完结
Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial
1个月前
已完结
New Option for Patients With Allergy to Chemotherapy Component
1个月前
已完结
Open issues in the therapeutic management of unresectable stage III NSCLC in the immunotherapy era
1个月前
已完结
Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer
1个月前
已完结
A Glimpse Into the Future for Unresectable Stage III Non-Small Cell Lung Cancer
1个月前
已完结
皖公网安备34019202002308
